MIRABEGRON
Total Payments
$2.9M
Transactions
1,402
Doctors
78
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $2.9M | 1,400 | 78 |
| 2017 | $7,089 | 2 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.6M | 803 | 90.2% |
| Consulting Fee | $132,999 | 25 | 4.6% |
| Travel and Lodging | $96,439 | 364 | 3.4% |
| Food and Beverage | $35,000 | 205 | 1.2% |
| Space rental or facility fees (teaching hospital only) | $9,500 | 2 | 0.3% |
| Royalty or License | $8,000 | 2 | 0.3% |
| Education | $41.50 | 1 | 0.0% |
Payments by Type
Research
$2.6M
803 transactions
General
$281,979
599 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder OAB Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms LUTS Due to Benign Prostatic Hyperplasia BPH | Astellas Pharma Global Development | $1.9M | 3 |
| A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder OAB | Astellas Pharma Global Development | $291,936 | 2 |
| A DOUBLE BLIND PLACEBO CONTROL TRIAL OF MIRABEGRON FOR MEDICAL EXPULSIVE THERAPY AND TO MANAGE STENT PAIN FOR URETERAL STONES Protocol 01-16-20-02 | Astellas Pharma Global Development | $86,950 | 0 |
| Mirabegron for Erectile Dysfunction | Astellas Pharma Global Development | $51,547 | 0 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder OAB PILLAR | Astellas Pharma Global Development | $47,602 | 4 |
| Mirabegron and Urinary Incontinence The Clinical Response and the Female Urinary Microbiome | Astellas US Technologies | $35,609 | 0 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms LUTS Due to Benign Prostatic Hyperplasia BPH | Astellas Pharma Global Development | $33,775 | 1 |
| A study of Mirabegron and pelvic floor rehabilitation for Overactive Bladder in Multiple Sclerosis. MIRROR | Astellas Pharma Global Development | $33,722 | 0 |
| Does Mirabegron Improve Disordered Sleep in Subjects with Lower Urinary Tract Symptoms LUTS | Astellas Pharma Global Development | $30,923 | 0 |
| AN OPEN-LABEL, BASELINE-CONTROLLED, MULTICENTER, PHASE 3 DOSE-TITRATION STUDY FOLLOWED BY A FIXED-DOSE OBSERVATION PERIOD TO EVALUATE EFFICACY, SAFETY AND PHARMACOKINETICS OF MIRABEGRON IN CHILDREN AND ADOLESCENTS FROM 5 TO LESS THAN 18 YEARS OF AGE WITH NEUROGENIC DETRUSOR OVERACTIVITY NDO ON CLEAN INTERMITTENT CATHETERIZATION CIC | Astellas Pharma Global Development | $29,903 | 0 |
| Pilot feasibility study of Mirabegron to treat UUI in elderly women | Astellas Pharma Global Development | $24,896 | 0 |
| A Pilot Study of Mirabegron and Behavioral Modification including Pelvic Floor Exercise for Overactive Bladder in Parkinson Disease | Astellas Pharma Global Development | $9,425 | 0 |
| A Prospective, Non-interventional, Registry Study of Patients Initiating a Course of DrugTherapy for Overactive Bladder OAB | Astellas Pharma Global Development | $4,092 | 1 |
| Prospective, Non-interventional, Registry Study of Patients Initiating a Course of DrugTherapy for Overactive Bladder OAB | Astellas Pharma Global Development | $3,195 | 1 |
| A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder OAB | Astellas Pharma Global Development | $3,195 | 1 |
| The efficacy and safety of mirabegron relative to onabotulinumtoxinA in patients with overactive bladder not appropriately managed with an antimuscarinic a network meta-analysis | Astellas Pharma Global Development | $3,045 | 1 |
| A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder | Astellas Pharma Global Development | $3,005 | 4 |
| ACB Scales & Measures White Paper | Astellas Pharma Global Development | $2,900 | 1 |
| 178-MA-3145 | Astellas Pharma Global Development | $2,760 | 1 |
| A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder | Astellas Pharma Global Development | $2,711 | 1 |
Top Doctors Receiving Payments for MIRABEGRON
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Oklahoma City, OK | $2.4M | 629 |
| , MD | Cardiovascular Disease | Los Angeles, CA | $134,110 | 6 |
| , MD | Urology | Brighton, MA | $44,985 | 119 |
| , MD | Urology | Greensboro, NC | $23,245 | 28 |
| , MD | Urology | Charleston, SC | $20,606 | 19 |
| , MD | Urology | Nashville, TN | $17,400 | 17 |
| , M.D | Urology | Webster, TX | $14,315 | 32 |
| , MD | Urology | San Antonio, TX | $10,652 | 30 |
| Eli Engel | — | Reseda, CA | $10,370 | 7 |
| , M.D | Urogynecology and Reconstructive Pelvic Surgery | Evanston, IL | $9,484 | 8 |
| , M.D | Urology | Putnam, CT | $9,121 | 17 |
| , M.D | Urology | Ann Arbor, MI | $8,781 | 13 |
| , M.D | Family Medicine | Jackson, MI | $8,707 | 21 |
| , MD | Urology | Dallas, TX | $8,625 | 5 |
| , MD | Urogynecology and Reconstructive Pelvic Surgery | Charlotte, NC | $8,360 | 15 |
| , MD | Urology | Columbus, OH | $8,202 | 16 |
| , M.D | Urology | Baltimore, MD | $8,162 | 10 |
| , MD | Urology | Cleveland, OH | $7,625 | 15 |
| , M.D | Urology | Baltimore, MD | $7,376 | 6 |
| , MD | Gynecology | Orange, CA | $7,373 | 10 |
| , MD | Urology | Dallas, TX | $7,073 | 11 |
| , MD | Hypertension Specialist | Farmington, CT | $4,750 | 28 |
| , M.D | Urology | Houston, TX | $4,333 | 11 |
| , MD | Family Medicine | Oceanside, CA | $4,149 | 4 |
| , MD | Obstetrics & Gynecology | Cleveland, OH | $3,228 | 3 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $2.6M
- Astellas Pharma US Inc $224,875
- Astellas US Technologies $35,609
- Astellas Pharma Inc $8,000
- Astellas Pharma Europe BV $730.00
Product Information
- Type Drug
- Total Payments $2.9M
- Total Doctors 78
- Transactions 1,402
About MIRABEGRON
MIRABEGRON is a drug associated with $2.9M in payments to 78 healthcare providers, recorded across 1,402 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2017 to 2018. In 2018, $2.9M was paid across 1,400 transactions to 78 doctors.
The most common payment nature for MIRABEGRON is "Unspecified" ($2.6M, 90.2% of total).
MIRABEGRON is associated with 20 research studies, including "A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder OAB Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms LUTS Due to Benign Prostatic Hyperplasia BPH" ($1.9M).